This milestone shows the devotion of our QA team to ensuring HEMEX’s high standards and commitment to quality. Achieving this certification was one of the milestones we wished to accomplish in 2022.
Collaboration Funding Innovation Press Release Regulatory
Revolutionising biomedical data sharing and AI-driven healthcare solutions
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue reading
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Only six months after closing its seed round of CHF 2.1 million, the successful healthtech start-up closes its pre-series A financing round of CHF 3.3 million. With this new capital, Sedimentum intends to conquer the Swiss B2C market with its intelligent SAFE-living solution.
Collaboration, Press Release
Resistell AG announces completion of clinical pilot Performance Evaluation Study
We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.
Welcome to the last article of HEMEX’s diversity series! Today we want to introduce you to our newest team member Manuela. Manuela grew up in Basel, Switzerland, and is currently studying medicine at the University of Basel. Curious about what brought her to HEMEX? Let’s keep reading and find out!
The Austrian biotech company is developing endolysins and phages as therapeutics, focusing on persistent bacterial infections that cannot be targeted with broad-spectrum antibiotics. This acquisition is a big step for the AMR crisis and the formerly Phagomed team. At HEMEX, we wanted to congratulate them on their fantastic job!
December 3rd is the international day of people with disabilities. Therefore, on this day, we’d like to raise awareness on the dignity and well-being of persons with disabilities while fostering a deeper understanding of the topic.
Continuing with HEMEX’s diversity series, we want to introduce you to our new team members Leonardo and Luana. Leonardo grew up in Milan, Italy, and Luana in the canton of Basel-Land, Switzerland. Both are dedicated to improving our society’s health system, and we are delighted with these new fresh ideas in our team! Do you want to know what brought them to HEMEX? Keep reading to find out.
HEMEX is pleased to announce the successful completion of another fundraising round. Following an oversubscribed first closing in February, our second closing of the Series C increased the round to CHF 7.1 million.
Following up on our diversity series, meet today Aurelia and Nycole. They are two outstanding young spirited women. At HEMEX, we are thrilled to have them on our team because they strengthen our work. Do you want to know a little more about their lives and how they ended up at HEMEX? Keep reading!